The effect of empagliflozin on peripheral microvascular dysfunction in heart failure with preserved ejection fraction

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-501682-45-00

Enrollment

Registered

2022-11-22

Start date

2023-02-13

Completion date

2024-12-01

Last updated

2022-12-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart failure with preserved ejection fraction

Brief summary

Cutaneous vascular conductance (CVC) (Skin blood flow divided by the mean arterial pressure) as measured by LASCA

Detailed description

Baseline bloodflow and area under the curve as measured by LASCA, Cutaneous vascular conductance (CVC), Serum ketone levels in mmol/L, EQ5D-5L questionnaire score

Interventions

DRUGMiochol®-E 10 mg/ml Pulver und Lösungsmittel zur Herstellung einer Instillationslösung zur intraokularen Anwendung

DRUGNIPRUSS 60 mg

DRUGpoeder voor oplossing voor infusie

DRUGNovoRapid 100 units/ml solution for injection in vial

DRUGJardiance 10 mg film-coated tablets

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Cutaneous vascular conductance (CVC) (Skin blood flow divided by the mean arterial pressure) as measured by LASCA	—

Secondary

Measure	Time frame
Baseline bloodflow and area under the curve as measured by LASCA, Cutaneous vascular conductance (CVC), Serum ketone levels in mmol/L, EQ5D-5L questionnaire score	—

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026